Moneycontrol
you are here: HomeNewsBusiness
Last Updated : Jul 12, 2018 02:59 PM IST | Source: PTI

Lupin gets USFDA nod to market antibacterial capsules

The approval from the United States Food and Drug Administration (USFDA) is to market the Nitrofurantoin capsules in the strengths of 50 mg and 100 mg, Lupin said in a statement.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Lupin today said it has received final approval from the US health regulator to market its antibacterial Nitrofurantoin capsules used for treating urinary tract infections.

The approval from the United States Food and Drug Administration (USFDA) is to market the Nitrofurantoin capsules in the strengths of 50 mg and 100 mg, Lupin said in a statement.

The product is a generic version of Alvogen Malta Operations Ltd's Macrodantin capsules in the same strengths, it added.

The capsules are indicated for the treatment of urinary tract infections caused by certain bacteria, Lupin said.

As per the IQVIA MAT April 2018 data Nitrofurantoin capsules USP 50 mg and 100 mg had annual sales of around USD 27 million in the US, it added.

Shares of Lupin were toady trading at Rs 899.15 per scrip on BSE, down 0.22 per cent from its previous close.
First Published on Jul 12, 2018 02:58 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant